Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
Dutton, Susan J, MSc, Ferry, David R, Prof, Blazeby, Jane M, Prof, Abbas, Haider, MRCP, Dahle-Smith, Asa, MBChB, Mansoor, Wasat, PhD, Thompson, Joyce, FRCP, Harrison, Mark, PhD, Chatterjee, Anirban, FRCR, Falk, Stephen, MD, Garcia-Alonso, Angel, MD, Fyfe, David W, MD, Hubner, Richard A, PhD, Gamble, Tina, Peachey, Lynnda, BSc, Davoudianfar, Mina, BA, Pearson, Sarah R, BSc, Julier, Patrick, MSc, Jankowski, Janusz, Prof, Kerr, Rachel, MD, Petty, Russell D, MRCP
Published in The lancet oncology (01.07.2014)
Published in The lancet oncology (01.07.2014)
Get full text
Journal Article
Patient-reported outcomes from a phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib (COG)
Dutton, Susan J., Blazeby, Jane M., Petty, Russell D., Mansoor, Wasat, Thompson, Joyce, Harrison, Mark, Abbas, Haider, Dahle-Smith, Asa, Chatterjee, Anirban, Falk, Stephen, Garcia-Alonso, Angel, Fyfe, David Walter, Hubner, Richard, Gamble, Tina, Peachey, Lynnda, Harvey, Christine, Julier, Patrick, Jankowski, Janusz, Midgley, Rachel, Ferry, David R.
Published in Journal of clinical oncology (01.02.2013)
Published in Journal of clinical oncology (01.02.2013)
Get full text
Journal Article